Cidara Therapeutics

Yahoo Finance • 4 days ago

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded NetEase (NTES) to Ov... Full story

Yahoo Finance • 5 days ago

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food... Full story

Yahoo Finance • 5 days ago

USVM's Underlying Holdings Imply 13% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 11 days ago

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an... Full story

Yahoo Finance • 18 days ago

Cidara Doses First Participants In Phase 3 ANCHOR Trial Of CD388 In High-Risk Flu Population

(RTTNews) - Cidara Therapeutics, Inc. (CDTX), a biotechnology company, on Friday announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of its drug candidate CD388 in populations at h... Full story

Yahoo Finance • 18 days ago

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN... Full story

Yahoo Finance • 20 days ago

Cidara jumps after expedited late-stage trial plan for flu therapy

[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] Cidara Therapeutics (NASDAQ:CDTX [https://seekingalpha.com/symbol/CDTX]) added ~15% on Wednesday after the biotech announced an accelerated timeline for a Phase 3... Full story

Yahoo Finance • 20 days ago

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA a... Full story

Yahoo Finance • 21 days ago

Cidara Therapeutics Reaches Analyst Target Price

In recent trading, shares of Cidara Therapeutics Inc (Symbol: CDTX) have crossed above the average analyst 12-month target price of $74.00, changing hands for $75.47/share. When a stock reaches the target an analyst has set, the analyst l... Full story

Yahoo Finance • last month

Cidara Therapeutics to Participate in September Investor Conferences

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company mana... Full story

Yahoo Finance • 2 months ago

Notable Wednesday Option Activity: VRT, CDTX, LMND

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertiv Holdings Co (Symbol: VRT), where a total of 65,043 contracts have traded so far, representing approximately 6.5 million und... Full story

Yahoo Finance • 2 months ago

Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress

Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $70.00 from $69.00 on Friday, while maintaining a Buy rating following the company’s second-quarter 2025 earnings release. The $1.37 billion m... Full story

Yahoo Finance • 2 months ago

Cidara Therapeutics stock price target raised to $66 at Citizens JMP

Investing.com - Citizens JMP has raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $66.00 from $59.00, while maintaining a Market Outperform rating. The company, currently valued at $1.37 billion, has seen its stock surge ove... Full story

Yahoo Finance • 2 months ago

RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential

Investing.com - RBC Capital raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $115.00 from $75.00 on Wednesday, while maintaining an Outperform rating. The biotech company, now valued at $1.35 billion, has delivered rem... Full story

Yahoo Finance • 3 months ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compen... Full story

Yahoo Finance • 3 months ago

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to... Full story

Yahoo Finance • 3 months ago

hVIVO reports positive results from Cidara's Phase 2b influenza study

LONDON - Contract research organization hVIVO PLC (AIM:HVO) announced Monday that its client Cidara Therapeutics (NASDAQ:CDTX) has achieved positive topline results in a Phase 2b field study for CD388, a drug designed to prevent seasonal i... Full story

Yahoo Finance • 4 months ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clos... Full story

Yahoo Finance • 4 months ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clo... Full story

Yahoo Finance • 4 months ago

Cidara Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pric... Full story